{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:48:20Z","timestamp":1791672500398,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07156-0","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T10:25:46Z","timestamp":1782555946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An assessment of the effectiveness of hydroxyurea therapy in children and adolescents with sickle cell anaemia at Kenyatta National Hospital"],"prefix":"10.1007","volume":"105","author":[{"given":"Madline Yacoub-Kenyi","family":"Leju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6562-0548","authenticated-orcid":false,"given":"Amsalu","family":"Degu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"1","key":"7156_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","volume":"14","author":"P Sundd","year":"2019","unstructured":"Sundd P, Gladwin MT, Novelli EM (2019) Pathophysiology of sickle cell disease. Annu Rev Pathol Mech Dis 14(1):263\u201392","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"3 Suppl 3","key":"7156_CR2","first-page":"2","volume":"34","author":"GP Rodgers","year":"1997","unstructured":"Rodgers GP (1997) Overview of pathophysiology and rationale for treatment of sickle cell anemia. Semin Hematol 34(3 Suppl 3):2\u20137","journal-title":"Semin Hematol"},{"key":"7156_CR3","doi-asserted-by":"crossref","unstructured":"\u00c1lvarez O, Wietstruck MA (2020) Sickle cell disease. In: Bertrand P, S\u00e1nchez I (eds) Pediatric Respiratory Diseases: A Comprehensive Textbook. Springer International Publishing, Cham, pp 529\u2013541","DOI":"10.1007\/978-3-030-26961-6_52"},{"issue":"1","key":"7156_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/asheducation-2009.1.62","volume":"2009","author":"RE Ware","year":"2009","unstructured":"Ware RE, Aygun B (2009) Advances in the use of hydroxyurea. Hematology (Am Soc Hematol Educ Program) 2009(1):62\u20139","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"4","key":"7156_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/inthealth\/ihu045","volume":"6","author":"PJ Carey","year":"2014","unstructured":"Carey PJ (2014) Addressing the global health burden of sickle cell disease. Int Health 6(4):269\u201370","journal-title":"Int Health"},{"issue":"6","key":"7156_CR6","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJMp2201763","volume":"387","author":"AE Zhou","year":"2022","unstructured":"Zhou AE, Travassos MA (2022) Bringing sickle-cell treatments to children in Sub-Saharan Africa. N Engl J Med 387(6):488\u201391","journal-title":"N Engl J Med"},{"key":"7156_CR7","unstructured":"World Health Organization (2024) WHO SICKLE package of interventions for sickle-cell disease management: strategic guidance framework: module 1. Brazzaville, WHO African Region"},{"issue":"11","key":"7156_CR8","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.3390\/ijerph19116871","volume":"19","author":"M Kilonzi","year":"2022","unstructured":"Kilonzi M, Mwakawanga DL, Felician FF, Mlyuka HJ, Chirande L, Myemba DT et al (2022) The Effects of Sickle Cell Disease on the Quality of Life: A Focus on the Untold Experiences of Parents in Tanzania. Int J Environ Res Public Health 19(11):6871","journal-title":"Int J Environ Res Public Health"},{"issue":"10","key":"7156_CR9","doi-asserted-by":"publisher","first-page":"e1458","DOI":"10.1016\/S2214-109X(19)30328-6","volume":"7","author":"S Uyoga","year":"2019","unstructured":"Uyoga S, Macharia AW, Mochamah G, Ndila CM, Nyutu G, Makale J et al (2019) The epidemiology of sickle cell disease in children recruited in infancy in Kilifi, Kenya: a prospective cohort study. Lancet Glob Heal 7(10):e1458\u2013e1466","journal-title":"Lancet Glob Heal"},{"issue":"9778","key":"7156_CR10","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","volume":"377","author":"WC Wang","year":"2011","unstructured":"Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP et al (2011) Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 377(9778):1663\u20131672","journal-title":"Lancet"},{"issue":"7","key":"7156_CR11","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood-2004-12-4973","volume":"106","author":"JS Hankins","year":"2005","unstructured":"Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP et al (2005) Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 106(7):2269\u20132275","journal-title":"Blood"},{"issue":"12","key":"7156_CR12","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1182\/blood-2009-05-221333","volume":"115","author":"E Voskaridou","year":"2010","unstructured":"Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G et al (2010) The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 115(12):2354\u201363","journal-title":"Blood"},{"issue":"2","key":"7156_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1813598","volume":"380","author":"L Tshilolo","year":"2019","unstructured":"Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A et al (2019) Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. N Engl J Med 380(2):121\u2013131","journal-title":"N Engl J Med"},{"issue":"12","key":"7156_CR14","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s40273-023-01294-3","volume":"41","author":"D Teigen","year":"2023","unstructured":"Teigen D, Opoka RO, Kasirye P, Nabaggala C, Hume HA, Blomberg B et al (2023) Cost-effectiveness of hydroxyurea for sickle cell anemia in a low-income African setting: a model-based evaluation of two dosing regimens. Pharmacoeconomics 41(12):1603\u201315","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"7156_CR15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/pbc.25705","volume":"63","author":"PT McGann","year":"2016","unstructured":"McGann PT, Tshilolo L, Santos B, Tomlinson GA, Stuber S, Latham T et al (2016) Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial. Pediatr Blood Cancer 63(1):98\u2013104","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"7156_CR16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3390\/ijerph22040616","volume":"22","author":"MI Subira","year":"2025","unstructured":"Subira MI, Ambrose EE, Konje E (2025) Adherence to hydroxyurea therapy for pediatric sickle cell anemia in Tanzania: evidence from Bugando Medical Centre. Int J Environ Res Public Health 22(4):616","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"7156_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-6-30","volume":"6","author":"I Paule","year":"2011","unstructured":"Paule I, Sassi H, Habibi A, Pham KP, Bachir D, Galact\u00e9ros F et al (2011) Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen. Orphanet J Rare Dis 6(1):30","journal-title":"Orphanet J Rare Dis"},{"key":"7156_CR18","unstructured":"Ministry of Health National Guidelines for Control and Management of Sickle Cell Disease in Kenya [Internet]. 2020 [cited 2026 Jan 9]. Available from: https:\/\/africasicklecell.org\/wp-content\/uploads\/2025\/07\/Sickle-Cell-Disease-Guidelines-Kenya_compressed.pdf?"},{"issue":"11","key":"7156_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10112223","volume":"10","author":"HJ Mlyuka","year":"2022","unstructured":"Mlyuka HJ, Kilonzi M, Mutagonda RF, Chirande L, Mikomangwa WP, Myemba DT et al (2022) Barriers and facilitators of availability of hydroxyurea for sickle cell disease in Tanzania; a qualitative study of pharmaceutical manufacturers, importers, and regulators. Healthcare (Basel) 10(11):2223","journal-title":"Healthcare (Basel)"},{"issue":"Supplement 1","key":"7156_CR20","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1182\/blood-2024-211859","volume":"144","author":"AOD Ofakunrin","year":"2024","unstructured":"Ofakunrin AOD, Olaosebikan R, Okpe ES, Diaku-Akinwumi I, Babiker S, Shehu M et al (2024) Barriers and Enablers to Hydroxyurea Adherence in Children and Adolescents with Sickle Cell Disease in Jos, Nigeria. Blood 144(Supplement 1):2517\u20132517","journal-title":"Blood"},{"issue":"04","key":"7156_CR21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.4236\/ojped.2015.54048","volume":"05","author":"IO George","year":"2015","unstructured":"George IO, Aiyedun CN (2015) Acute chest syndrome in children with sickle cell anaemia: an audit in Port Harcourt, Nigeria. Open J Pediatr 05(04):320\u20135","journal-title":"Open J Pediatr"},{"key":"7156_CR22","doi-asserted-by":"publisher","first-page":"2333794X1877497","DOI":"10.1177\/2333794X18774970","volume":"5","author":"LJ Marks","year":"2018","unstructured":"Marks LJ, Munube D, Kasirye P, Mupere E, Jin Z, LaRussa P et al (2018) Stroke Prevalence in Children With Sickle Cell Disease in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. Glob Pediatr Heal 5:2333794X18774970","journal-title":"Glob Pediatr Heal"},{"issue":"3","key":"7156_CR23","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.4314\/tjs.v47i3.25","volume":"47","author":"A Gangji","year":"2021","unstructured":"Gangji A, Masamu U, Mgaya J, Ndunguru J, Jonathan A, Minja IK et al (2021) Effects of Hydroxyurea Treatment on Haemolysis in Patients with Sickle Cell Disease at Muhimbili National Hospital, Tanzania. Tanzan J Sci 47(3):1165\u20131173","journal-title":"Tanzan J Sci"},{"issue":"7","key":"7156_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30332","volume":"70","author":"SL Reeves","year":"2023","unstructured":"Reeves SL, Dombkowski KJ, Peng HK, Phan H, Kolenic G, Creary SE et al (2023) Adherence to hydroxyurea and clinical outcomes among children with sickle cell anemia. Pediatr Blood Cancer 70(7):e30332","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"7156_CR25","doi-asserted-by":"publisher","first-page":"e27650","DOI":"10.1002\/pbc.27650","volume":"66","author":"SB Schuchard","year":"2019","unstructured":"Schuchard SB, Lissick JR, Nickel A, Watson D, Moquist KL, Blaylark RM et al (2019) Hydroxyurea use in young infants with sickle cell disease. Pediatr Blood Cancer 66(7):e27650","journal-title":"Pediatr Blood Cancer"},{"key":"7156_CR26","doi-asserted-by":"crossref","unstructured":"Piel FB, Steinberg MH, Rees DC (2017) Sickle Cell Disease. Longo DL, editor. N Engl J Med 376(16):1561\u201373","DOI":"10.1056\/NEJMra1510865"},{"issue":"24","key":"7156_CR27","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood-2017-06-788935","volume":"130","author":"RO Opoka","year":"2017","unstructured":"Opoka RO, Ndugwa CM, Latham TS, Lane A, Hume HA, Kasirye P et al (2017) Novel use of hydroxyurea in an African region with malaria (NOHARM): a trial for children with sickle cell anemia. Blood 130(24):2585\u201393","journal-title":"Blood"},{"issue":"3","key":"7156_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/tropej\/fmz070","volume":"66","author":"AOD Ofakunrin","year":"2020","unstructured":"Ofakunrin AOD, Oguche S, Adekola K, Okpe ES, Afolaranmi TO, Diaku-Akinwumi IN et al (2020) Effectiveness and safety of hydroxyurea in the treatment of sickle cell anaemia children in Jos, North Central Nigeria. J Trop Pediatr 66(3):290\u20138","journal-title":"J Trop Pediatr"},{"issue":"20","key":"7156_CR29","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","volume":"332","author":"S Charache","year":"1995","unstructured":"Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV et al (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332(20):1317\u201322","journal-title":"N Engl J Med"},{"issue":"11","key":"7156_CR30","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1136\/archdischild-2012-302387","volume":"98","author":"M Mulaku","year":"2013","unstructured":"Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M (2013) Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. Arch Dis Child 98(11):908\u2013914","journal-title":"Arch Dis Child"},{"issue":"1","key":"7156_CR31","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/S2352-3026(21)00368-9","volume":"9","author":"SU Abdullahi","year":"2022","unstructured":"Abdullahi SU, Jibir BW, Bello-Manga H, Gambo S, Inuwa H, Tijjani AG et al (2022) Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial. Lancet Haematol 9(1):e26\u201337","journal-title":"Lancet Haematol"},{"issue":"9757","key":"7156_CR32","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","volume":"376","author":"DC Rees","year":"2010","unstructured":"Rees DC, Williams TN, Gladwin MT (2010) Sickle-cell disease. Lancet 376(9757):2018\u20132031","journal-title":"Lancet"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07156-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07156-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07156-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:50:34Z","timestamp":1791669034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07156-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["7156"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07156-0","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval for the study was obtained from the Kenyatta National Hospital\u2013University of Nairobi Ethics and Research Committee (Approval No: KNH-ERC\/UA\/317). Access to patient medical records was granted only after formal authorization from relevant hospital authorities. To protect confidentiality, patient names and direct identifiers were not recorded; instead, unique identification codes were assigned. Data were securely stored and accessible only to authorized research personnel. All study procedures complied with the Declaration of Helsinki and the Kenyan Data Protection Act (2019).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"417"}}